Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis.

Authors

• Hongmei Li
• Patricia Gonnella
• Farinaz Safavi
• Ghazal Vessal
• Bardia Nourbakhsh
• Fang Zhou
• Guang-Xian Zhang
• Abdolmohamad Rostami

Publication/Presentation Date

1-15-2013

Abstract

Zymosan has previously been reported to have both pro-inflammatory and anti-inflammatory effects. Here we demonstrate that low dose zymosan prevented or reversed chronic and relapsing paralysis in EAE. In suppressing CNS autoimmune inflammation, zymosan not only regulated APC costimulator and MHC class II expression, but also promoted differentiation of regulatory T cells. Following adoptive transfer of zymosan-primed CD4(+) T cells, recipient mice were protected from EAE. In contrast, a MAPK inhibitor and a blocker of β-glucan, reversed the effects of zymosan. These results demonstrate that zymosan may be a promising beneficial agent for Multiple Sclerosis (MS).

Volume

254

Issue

1-2

First Page

28

Last Page

38

ISSN

1872-8421

Published In/Presented At

Li, H., Gonnella, P., Safavi, F., Vessal, G., Nourbakhsh, B., Zhou, F., Zhang, G. X., & Rostami, A. (2013). Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis. Journal of neuroimmunology, 254(1-2), 28–38. https://doi.org/10.1016/j.jneuroim.2012.08.013

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

23010280

Department(s)

Administration and Leadership

Document Type

Article